Cargando…
Sclerostin and Vascular Pathophysiology
There is cumulating evidence for a contribution of Wnt signaling pathways in multiple processes involved in atherosclerosis and vascular aging. Wnt signaling plays a role in endothelial dysfunction, in the proliferation and migration of vascular smooth muscle cells (VSMCs) and intimal thickening. Mo...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7370046/ https://www.ncbi.nlm.nih.gov/pubmed/32640551 http://dx.doi.org/10.3390/ijms21134779 |
_version_ | 1783560909837303808 |
---|---|
author | Catalano, Antonino Bellone, Federica Morabito, Nunziata Corica, Francesco |
author_facet | Catalano, Antonino Bellone, Federica Morabito, Nunziata Corica, Francesco |
author_sort | Catalano, Antonino |
collection | PubMed |
description | There is cumulating evidence for a contribution of Wnt signaling pathways in multiple processes involved in atherosclerosis and vascular aging. Wnt signaling plays a role in endothelial dysfunction, in the proliferation and migration of vascular smooth muscle cells (VSMCs) and intimal thickening. Moreover, it interferes with inflammation processes, monocyte adhesion and migration, as well as with foam cell formation and vascular calcification progression. Sclerostin is a negative regulator of the canonical Wnt signaling pathway and, accordingly, the consequence of increased sclerostin availability can be disruption of the Wnt signalling cascade. Sclerostin is becoming a marker for clinical and subclinical vascular diseases and several lines of evidence illustrate its role in the pathophysiology of the vascular system. Sclerostin levels increase with aging and persist higher in some diseases (e.g., diabetes, chronic kidney disease) that are known to precipitate atherosclerosis and enhance cardiovascular risk. Current knowledge on the association between sclerostin and vascular diseases is summarized in this review. |
format | Online Article Text |
id | pubmed-7370046 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-73700462020-07-21 Sclerostin and Vascular Pathophysiology Catalano, Antonino Bellone, Federica Morabito, Nunziata Corica, Francesco Int J Mol Sci Review There is cumulating evidence for a contribution of Wnt signaling pathways in multiple processes involved in atherosclerosis and vascular aging. Wnt signaling plays a role in endothelial dysfunction, in the proliferation and migration of vascular smooth muscle cells (VSMCs) and intimal thickening. Moreover, it interferes with inflammation processes, monocyte adhesion and migration, as well as with foam cell formation and vascular calcification progression. Sclerostin is a negative regulator of the canonical Wnt signaling pathway and, accordingly, the consequence of increased sclerostin availability can be disruption of the Wnt signalling cascade. Sclerostin is becoming a marker for clinical and subclinical vascular diseases and several lines of evidence illustrate its role in the pathophysiology of the vascular system. Sclerostin levels increase with aging and persist higher in some diseases (e.g., diabetes, chronic kidney disease) that are known to precipitate atherosclerosis and enhance cardiovascular risk. Current knowledge on the association between sclerostin and vascular diseases is summarized in this review. MDPI 2020-07-06 /pmc/articles/PMC7370046/ /pubmed/32640551 http://dx.doi.org/10.3390/ijms21134779 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Catalano, Antonino Bellone, Federica Morabito, Nunziata Corica, Francesco Sclerostin and Vascular Pathophysiology |
title | Sclerostin and Vascular Pathophysiology |
title_full | Sclerostin and Vascular Pathophysiology |
title_fullStr | Sclerostin and Vascular Pathophysiology |
title_full_unstemmed | Sclerostin and Vascular Pathophysiology |
title_short | Sclerostin and Vascular Pathophysiology |
title_sort | sclerostin and vascular pathophysiology |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7370046/ https://www.ncbi.nlm.nih.gov/pubmed/32640551 http://dx.doi.org/10.3390/ijms21134779 |
work_keys_str_mv | AT catalanoantonino sclerostinandvascularpathophysiology AT bellonefederica sclerostinandvascularpathophysiology AT morabitonunziata sclerostinandvascularpathophysiology AT coricafrancesco sclerostinandvascularpathophysiology |